ArticleJCEM case reports2025
A Report of 3 Cases of Adrenal Suppression Due to Glucocorticoid Hypersensitivity to Inhaled Corticosteroids.
Article in JCEM case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Children with moderate to severe asthma are treated with inhaled corticosteroids (ICS). Altered glucocorticoid sensitivity can cause suppression of the hypothalamic-pituitary-adrenal (HPA) axis in patients on ICS therapy. Our objective is to study glucocorticoid sensitivity in patients with asthma with suppressed HPA axes on ICS. We report 3 patients with suppressed HPA axes on ICS treatment and healthy controls. All subjects and controls underwent glucocorticoid sensitivity analysis using an in vitro fluorescein labeled-dexamethasone (F-DEX) mononuclear cell binding assay. Glucocorticoid sensitivity index (GCSI) was calculated as the area under the curve of the F-DEX assay results. Patients with GCSI ≤264 were classified as glucocorticoid resistant and those with GCSI ≥386 were classified as having increased glucocorticoid sensitivity. All 3 patients were found to have increased glucocorticoid sensitivity with GCSI of 424.9, 720.6, and 699.2 respectively. In conclusion, ICS therapy can lead to HPA axis suppression with varying degrees of adrenal insufficiency and therefore increased glucocorticoid sensitivity should be considered in such cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.